We next tested whether co-administration of the orally-available, CREBBP bromodomain inhibitor Inobrodib, which is in early-phase trials in hematological malignancies, could sensitize 697WT cells to Venetoclax in-vivo (Supplementary Fig. 9e). Here, CREBBP is linked to hematologic disorder.